HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
- Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
- Shionogi Submits PIIa Clinical Trial Application for OncoTherapy’s AMD Vaccine
March 23, 2012
- Ajinomoto Pharmaceuticals to Market Gastritis/Ulcer Treatment Marzulene from July
March 23, 2012
- Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
- India’s Ministry of Commerce and Industry Kicks Off “Brand India Pharma” Campaign
March 22, 2012
- BD Japan Seeking Further Partnerships with Japanese Companies: Pres. Harris
March 22, 2012
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
- Taiho Pharmaceutical Launches TS-1 in 4 Scandinavian Countries
March 22, 2012
- Acquisition by Lupin Improves Kyowa Pharmaceutical Industry’s Profitability: President Tsunoda
March 21, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…